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Abstract
The kinetics of T and B cell immune recovery after bone marrow transplantation (BMT) is affected by many pre- and post-
transplant factors. Because of the profoundly depleted baseline T and B cell immunity in recombination activating gene 2
(RAG-2)-deficient severe combined immunodeficiency (SCID) patients, some of these factors are eliminated, and the
immune recovery after BMT can then be clearly assessed. This process was followed in ten SCID patients in parallel to their
associated transplant-related complications. Early peripheral presence of T and B cells was observed in 8 and 4 patients,
respectively. The latter correlated with pre-transplant conditioning therapy. Cells from these patients carried mainly signal
joint DNA episomes, indicative of newly derived B and T cells. They were present before the normalization of the T cell
receptor (TCR) and the B cell receptor (BCR) repertoire. Early presentation of the ordered TCR gene rearrangements after
BMT occurred simultaneously, but this pattern was heterogeneous over time, suggesting different and individual thymic
recovery processes. Our findings early after transplant could suggest the long-term patients’ clinical outcome. Early
peripheral presence of newly produced B and T lymphocytes from their production and maturation sites after BMT suggests
donor stem cell origin rather than peripheral expansion, and is indicative of successful outcome. Peripheral detection of TCR
excision circles and kappa-deleting recombination excision circles in RAG-2-deficient SCID post-BMT are early markers of T
and B cell reconstitution, and can be used to monitor outcome and tailor specific therapy for patients undergoing BMT.
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Introduction
Severe combined immunodeficiency (SCID) is characterized by
significantly low levels of T and B cells and profound defective
immune function. Bone marrow transplantation (BMT) is the life-
saving and life-sustaining treatment procedure for such patients in
order to restore their T and B cell immunity [1]. After BMT, the
three main goals that are extremely important for achieving long-
term survival in these patients include engraftment of the
transfused stem cells, prevention of graft versus host disease
(GVHD) and neogenesis of functionally diverse and matured T
and B cells [2]. The kinetics of early T and B cell recovery after
BMT, occurring during the first three months post-BMT, has a
major impact on achieving these goals.
The thymus and the bone marrow are the primary anatomic
sites for T and B cell neogenesis from undifferentiated hemato-
poietic progenitor cells. Within these organs, hematopoietic
progenitor cells that have been committed to the T and B cell
lineage undergo rapid proliferation and differentiation to mature
cells. During this process, a diverse receptor repertoire is formed,
and the resulting cells are able to respond to a wide array of
internally and externally processed antigens [3–5]. Normally, T
cell maturation in the thymus progresses through distinct stages
which are defined phenotypically by the expression of the T cell
receptor (TCR) and the CD4 and CD8 co-receptors. On the basis
of the expression of these cell surface markers and the ordered
gene rearrangements, thymocytes represent different maturation
steps on their way to becoming mature cells [6]. On the one hand,
DNA strand breakage during the thymic and bone marrow
maturation processes of the TCR a/b chains and the B cell
receptor (BCR) light and heavy chains, respectively, creates
functional receptors (i.e., the formation of coding joint recombi-
nation sites), while, on the other hand, it creates byproducts (i.e.,
the formation of signal joint recombination sites) termed TCR
excision circles (TRECs) and kappa-deleting recombination
excision circles (KRECs), respectively [7]. TREC quantification
is extensively used as an accurate measure of thymic function and
T cell neogenesis, and this analysis was therefore suggested as a
diagnostic tool for T cell immunodeficiency [8], for neonatal
screen assay to detect SCID immediately after birth [9], and as
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reconstitution after BMT [10]. KRECs form the extra-chromo-
somal (episomal) excision product of the immunoglobulin gene
rearrangement. Similar to TRECs, these episomal products
cannot replicate in the cell. KRECs appear to be highly stable
structures, which can persist for a considerable length of time in
peripheral blood. The ratio between genomic coding joints and
signal joints on these circles reflects both B cell neogenesis and the
replication history of B lymphocyte subsets. As such, KRECs can
be found not only in precursor B cells but in mature B
lymphocytes as well [11]. After BMT, the detection of KRECs
reflects newly derived functional bone marrow B cells.
A major challenge in the field of BMT is the overcoming the
difficulty of monitoring the efficacy of the procedure, especially
since the prognosis is affected by many pre- and post-transplant
parameters [1]. Ideally, T and B cells should regenerate from stem
cells present in the graft, and various BMT procedure manipu-
lations, such as pre-transplant conditioning therapy, are performed
in order to ensure its occurrence. Recombination activating genes
1 and 2 (RAG-1 and RAG-2) are the two essential and tissue-
specific components for the generation of antigen-binding diversity
by assembly of the variable (V), diversity (D), and joining (J) DNA
segments at both the immunoglobulin and TCR gene loci during
lymphocyte development. Therefore, assessment of T and B cell
regeneration can be clearly demonstrated in SCID patients with
RAG-1 or RAG-2 defects after BMT. Unlike other SCID variants,
RAG-deficient patients suffer from low numbers of T and B cells,
and the cells that they do have are dysfunctional. Thus, the
detection of T and B cell undergoing neogenesis and the
measurement of a broad formed repertoire in RAG-deficient
SCID patients depend primarily on the differentiation of cells
originating from donor undifferentiated hematopoietic progenitor
cells and not from the host cells.
In the present study, we examined the early release of newly
formed T and B cells from the thymus and the bone marrow in the
peripheral blood of 10 RAG-2-deficient SCID patients who
received a transplantation of hematopoietic stem cells from healthy
donors. This experimental population provides a unique oppor-
tunity to examine immune reconstitution and to identify clinical
factors that influence the rapidity and extent of T and B cell
neogenesis in vivo.
Methods
Patients
Ten consecutive patients diagnosed at the Sheba Medical
Center (Tel Hashomer, Israel) as having RAG-2-deficient SCID
were enrolled in this study which was approved by the Institutional
Review Board. Parents provided signed informed consent to
obtain blood from their children. Diagnosis was based on clinical
findings, family history, and immunological evaluation, and
confirmed by genetic testing. Patients who lacked histocompatible
siblings or closely matched related donors (MRD) received match
unrelated donor (MUD) or mismatch related donor (MMRD)
Table 1. List of primers used by real time PCR analysis to detect the amount of TRECs, signal joint KRECs, coding joint KRECs and
the various TCR rearrangements.
Forward primer (59-39) Reverse primer (59-39) Taqman probe (FAM-TAMRA) (59-39)
TREC CACATCCCTTTCAACCATGCT GCCAGCTGCAGGGTTTAGG ACACCTCTGGTTTTTGTAAAGGTGCCCACT
TCRD-d/D2-D3 CAAGGAAAGGGAAAAAGGAAGAA TTGCCCCTGCAGTTTTTGTAC ATACGCACAGTGCTACAAAACCTACAGAGACCT
TCRD-d/D2-J1 AGCGGGTGGTGATGGCAAAGT TTAGATGGAGGATGCCTTAACCTTA CCCGTGTGACTGTGGAACCAAGTAAGTAACTC
TCRD-d/V1-J1 ATGCAAAAAGTGGTCGCTATT TTAGATGGAGGATGCCTTAACCTTA CCCGTGTGACTGTGGAACCAAGTAAGTAACTC
TCRA-REC AAAAAGCAACATCACTCTGTGTCT GGCACATTAGAATCTCTCACTGA CCAGAGGTGCGGGCCCCA
KREC-SJ TCAGCGCCCATTACGTTTCT GTGAGGGACACGCAGCC CCAGCTCTTACCCTAGAGTTTCTGCACGG
KREC-CJ CCCGATTAATGCTGCCGTAG CCTAGGGAGCAGGGAGGCTT AGCTGCATTTTTGCCATATCCACTATTTGGAGT
doi:10.1371/journal.pone.0030494.t001
Table 2. The clinical features of the SCID patients and their specific RAG2 genetic defect.
Patient Age at diagnosis months Sex Family history Clinical presentation RAG2 Genetic defect
P1 3 M + SCID-Omenn G35V
P2 3 M + SCID G35V
P3 6 M 2 SCID T215I
P4 3 F + SCID G35V
P5 1 M + SCID G35V
P6 1 F + SCID T215I
P7 4 F + SCID-Omenn T215I
P8 3 M + SCID-Omenn G35V
P9 3 M 2 SCID-Omenn G95V+E480X
P10 3 M 2 SCID –100% maternal engraftment G156V
SCID – severe combined immunodeficiency.
doi:10.1371/journal.pone.0030494.t002
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Lymphocytes in all patients were tested for human leukocyte
antigen (HLA) A, B, C and DR typing using standard serological
methods, or DNA hybridization with sequence-specific oligonu-
cleotide probes in order to find a suitable donor.
Transplantation procedures
The patients were treated in positive pressure with heap filter
units from the time of diagnosis until discharge. Trimethoprim/
sulfametaxozole was used for Pneumocystis jiroveci prophylaxis.
Intravenous immunoglobulins (IVIG, 600 mg/kg) were infused to
maintain IgG levels above 6 g/l. Acyclovir (1500 mg/m
2/day)
was administered to patients who received bone marrow from
cytomegalovirus (CMV)-seropositive donors or to CMV-seropos-
itive patients who received stem cell transplantation from a
seronegative donor. All blood products were CMV safe and
irradiated. Pre-transplant conditioning therapy consisting of
various drugs was given to some patients, and the severity of
GVHD was graded as described previously [10]. It was defined as
being chronic if it presented or occurred more than 100 days after
transplant, even though the symptoms were often similar to acute
GVHD. GVHD prophylaxis, administered to some patients from
the day prior to transplant, consisted of cyclosporin A combined
with methotrexate. All patients were infused with non-depleted 3–
56108 donor bone marrow mononuclear cells per kg of recipient
weight. They received granulocyte colony stimulating factor (G-
CSF) from the day of transplant until the absolute neutrophil
count was .1.0610
9/l for 3 consecutive days.
Table 3. Pre-BMT immune workup of the 10 RAG2-deficient SCID patients, including flow cytometry analysis, and cell-mediated
and humoral-immune evaluations.
Patient
Flow cytometry analysis of patients by lymphocytes
(in 10
6/L)
Cell mediated
immunity Humoral immunity
ALC
(3500–9000)
CD3
(1900–5900)
CD4
(1400–4300)
CD8
(500–1700)
CD19
(600–2600)
CD56
(160–950) PHA - SI TCR
TREC
(.400)
IgG
(230–1400)
IgA
(0–80)
IgM
(0–140)
P1 5250 4410 3675 1050 0 350 2% UD UD UD UD UD
P 2 1 6 2 4 0000 1 5 3 2 1 % U D U D U D U D U D
P3 600 240 144 90 0 300 1.2% UD UD 33 6 9
P4 1797 29 20 7 7 1500 0.1% clonal UD 62 8 4
P 5 2 2 1 7611 2 0 0 0 . 5 % U D U D U D U D U D
P6 1190 62 46 109 0 700 6.4% UD UD 1120 UD 25
P7 1983 1051 892 297 0 380 ND clonal UD UD UD UD
P8 1320 488 224 224 0 475 10.9% clonal UD UD UD UD
P9 10686 2871 2351 855 0 3800 605% clonal UD UD UD 110
P10 5600 4612 2855 1757 1 504 3.8% clonal UD 433 79 UD
Control levels are presented in bracket.
ND – not done, UD- undetectable, PHA – phytohemagglutinin, SI – stimulation index (patient/control), TCR - T cell receptor, TREC - TCR excision circles (copies per
0.5 mcg DNA), ALC - absolute lymphocyte count.
doi:10.1371/journal.pone.0030494.t003
Table 4. Characteristics of the BMT procedure and its related complications.
Patient Donor
Year
of BMT
Age at BMT
(month)
Follow-up
(months) Conditioning Graft Prophylaxis
Neutrophils
(days) Acute GVHD
Febrile
episodes
P1 MMRD 2005 4 36 No PBSC/CD34 No 25 grade IV 2
P2 MMRD 2005
2006
4
7
22 No PBSC/CD34 No 28 grade IV 2
P3 MRD 1998 7.5 146 No BM No 13 No 1
P4 MMRD 2002 4 92 No PBSC/CD34 No 10 No 0
P5 MMRD 2000 1.5 132 No PBSC/CD34 No 10 grade III 2
P6 MRD 2000 1 119 No BM No 11 No 1
P7 MMRD 1997 5 150 Bu Cy ATG PBSC/CD34 CSA 8 grade III 2
P8 MRD 2008 7.5 25 Tre Flu Thi BM CSA+MTX 15 grade II 1
P9 MUD 2010 5 4 Bu Cy ATG UCB CSA 13 grade I 1
P10 MMRD 2009 5 9 Flu, Mel, Thi OKT3 PBSC/CD34 MMF 9 No 2
MRD - match related donors, MUD - match unrelated donor, MMRD - mismatch related donor, Bu – Busulfan, Cy – cyclophosphamide, ATG – anti thymocytes globulin,
Tre – Treosulfan, Flu – Fludarabine, Thi – Thiotepa, Mel – melphalan, PBSC –peripheral blood stem cells, BM – Bone marrow, UCB – Umbilical cord blood, CSA–
Cyclosporin, MTX – methotrexate, MMF – mycophenolate mofetil.
doi:10.1371/journal.pone.0030494.t004
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Neutrophil engraftment was considered to have occurred on the
first of 3 consecutive days in which the absolute neutrophil count
exceeded 0.5610
9/l. Lymphocytes were analyzed for long-term
donor engraftment by polymerase chain reaction (PCR) of
polymorphic markers. Multiplex tetranucleotide repeat PCR was
performed on 2 ng of genomic DNA using the AmpFlSTR SGM
Plus kit (Applied Biosystems), which amplifies 10 tetranucleotide
repeat loci (plus the X–Y homologous gene amelogenin) labeled in
three different colors (blue 5-FAM, green JOE and yellow NED).
Amplified PCR products were subjected to capillary electropho-
resis in an ABI Prism 3100 (Applied Biosystems) automated DNA
sequencer under the conditions recommended by the manufac-
turer. The GeneScan 3.7 Analysis software (Applied Biosystems)
was used for the analysis of the PCR products.
Lymphocyte markers and T-cell proliferative responses
Cell surface markers of peripheral blood mononuclear cells
(PBMCs), using immunofluorescent staining and flow cytometry
(Epics V; Coulter Electronics, Hialeah, FL) with antibodies
purchased from Coulter Diagnostics, and lymphocyte proliferation
in response to phytohemagglutinin, using tritiated thymidine
incorporation, were determined as previously described [12]. For
lymphocyte proliferation studies, cells were harvested 3 days after
transplantation and samples were counted in a liquid scintillation
counter. All assays were performed in triplicate, and a stimulation
index (SI) was calculated as the ratio between stimulated and
unstimulated lymphocyte responses and compared with the SI
obtained from normal controls. Serum concentrations of immu-
noglobulins were measured using nephelometry.
BCR and TCR gene rearrangement analyses
TCR and BCR gene rearrangement analyses were performed
on genomic DNA obtained from patient’s PBMCs without specific
cell enrichment, as previously described.
8 Briefly, the immuno-
globulin heavy chain (IGH) and TCR-c genes were amplified by
PCR using fluorescence-labeled Vh primers or Vc primers,
respectively, according to the standardized Biomed 2 protocol.
Fluorescence-labeled PCR products (1 ml of each) were added to a
mixture of 8.5 ml deionized formamide and 0.5 ml GeneScan
500TM Rox internal lane standard (PE Applied Biosystem,
Germany), and separated using the 3100 Genetic Analyzer
(Applied Biosystem). Results were analyzed using the GeneMap-
per software (Applied Biosystem).
Quantification of TRECs and KRECs
The amount of TRECs was determined by real-time quanti-
tative (RQ)-PCR. Reactions were performed using 0.25 mg
genomic DNA extracted from the patient’s PBMCs. PCR
reactions contained TaqMan universal PCR master mix (Applied
Biosystems,), specific primers (900 nM) and FAM-TAMRA probes
(250 nM) as previously described [8] (Table 1). RQ-PCR was
carried out in an ABI PRISM 7900 Sequence Detector System
(Applied Biosystems). The standard curve was constructed by
using serial dilutions of a known TREC plasmid (generously
provided by Dr. Daniel Douek, Vaccine Research Center,
National Institute of Allergy and Infectious Diseases, Bethesda,
MD). The dilutions contained 10
3 to 10
6 copies of the signal joint
TREC plasmid. A triplicate was used for each dilution. The
obtained cycle threshold (Ct) values of the standard curve were the
same in all experiments 60.5 cycle: 20.8 cycles for 10
6 copies, 23.6
cycles for 10
5 copies, 27.7 cycles for 10
4 copies, and 30.1 cycles for
10
3 copies. TREC copies were .400 in 40 samples in which
immunodeficiency was ruled out. The number of TRECs in a
given sample was automatically calculated by comparing the
obtained Ct value of a patient’s sample to the standard curve using
an absolute quantification algorithm.
TheamountofsignalandcodingjointofKRECswasdetermined
by RQ-PCR as described for TRECs above. In order to calculate
the change in KREC copies for each patient, the obtained Ct was
compared to the Ct of his/her KREC levels before undergoing
BMT using the LLCt relative quantification analysis. Amplification
of RNAseP (TaqMan assay, Applied Biosystems) served as a quality
control to verify similar amounts of genomic DNA that were used in
the assays for both the TREC and KREC analyses. Age-matched
normal individuals were used as controls. Each experiment was
performed in triplicate, and the threshold line for Ct determination
was positioned at the same level.
Analysis of ordered human TCR gene rearrangement
The amount of copies of various TCR gene rearrangements in a
given sample was relatively quantified using RQ-PCR methodol-
ogy as described above. The primers and probes are listed in
Table 1. In order to calculate the fold of change in these
rearrangements for each patient, the post-BMT Ct was compared
Table 5. Clinical outcome and cell -mediated and humoral-immune reconstitution after BMT in 10 RAG2-deficient SCID patients.
Patient
months
post BMT IVIG ALC CD3 CD4 CD8 CD56 CD20 PHA -SI IGG IGA IGM
Chimerism
in lymph (%) Outcome
P1 24 yes 632 430 152 316 90 6 2.6% 486 19 27 30 Died
P2 24 yes 1840 1564 846 644 60 18 62% ND ND ND 34 Died
P3 76 yes 873 306 279 105 20 61 35% 480 UD UD 100 Alive, cGVHD
P4 72 No 2134 1643 597 1003 105 192 39% 642 118 96 50 Alive, cGVHD
P5 120 yes 2346 1947 1173 868 115 47 50% 2180 63 401 100 Alive, cGVHD
P6 6 No 1212 720 480 300 40 120 260% ND ND ND 80 Alive and Well
P7 34 No 4506 3154 1262 1622 450 541 89% ND ND ND 100 Alive and Well
P8 30 No 5084 3711 2695 1118 200 763 86% 1120 75 78 100 Alive and Well
P9 3 yes 747 234 112 127 350 3 ND 1110 UD 20 100 Alive and Well
P10 8 yes 2702 1973 598 1189 270 162 ND 438 UD 18 100 Alive and Well
ND-not done, UD-undetectable, PHA – phytohemagglutinin, SI – stimulation index (patient/control), ALC - absolute lymphocyte count.
doi:10.1371/journal.pone.0030494.t005
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relative quantification analysis. Amplification of RNAseP (Taq-
Man assay, Applied Biosystems) was used as a quality control to
verify similar amounts of genomic DNA that were used in the
assays. Age-matched normal individuals were used as controls.
Each experiment was performed in triplicate, and the threshold
line for Ct determination was positioned at the same level.
Results
Patient population, characteristics and immune
evaluation prior to BMT
Patients were diagnosed based on clinical findings supplemented
by a basic immune workup and confirmed by genetic analysis. A
total of 10 consecutive RAG-deficient SCID patients (7 males and
3 females) were included in this study (Table 2). Their age at
diagnosis ranged from 1 to 6 months (mean 361.4 months). Seven
patients had a family history suggestive of primary immunodefi-
ciency. Three patients were diagnosed as having Omenn’s
syndrome. The findings of the patients’ immune evaluations prior
to BMT are summarized in Table 3.
BMT procedure, complications after BMT and survival
The mean age at transplantation was 6 months (range 3–9
months) (Table 4). Six patients received an MMRD transplant
using peripheral blood stem cell collection with CD34-positive
selection. Three patients received MRD transplant using bone
marrow and one received an MUD transplant using umbilical
Figure 1. Early presence of TREC and transplant-related mortality. TREC copies were detected in all studied patients (#1–#10) at either 2–4
months (a) or various time lengths (b) post-bone marrow transplant (BMT). TREC copies were determined by real-time quantitative (RQ) PCR and
calculated by comparing the obtained cycle threshold (Ct) value of a patient sample to the standard curve using an absolute quantification algorithm.
Each sample was detected in triplicate.
doi:10.1371/journal.pone.0030494.g001
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hospitalization (Table 4). They all occurred within a few days after
BMT while the patients were severely neutropenic, and all of them
recovered after receiving antibiotic therapy. Six patients (60%)
developed acute grade II or higher GVHD, which was reversed in
all cases. As expected, patients who received an MMRD were at
increased risk for developing acute GVHD. Eight patients are
currently alive and have been followed-up for 6–150 months after
BMT. Two patients (#1 and #2) succumbed to severe infections
22 and 36 months, respectively, after BMT. Patient #2 failed to
engraft and a repeat MMRD BMT was performed 12 months
after the first one. Of the 8 surviving patients, 4 (#6–8 and 10) are
well and live normal lives, 3 (#3–5) still suffer from severe chronic
GVHD (cGVHD), and 1 (#9) is still on prophylactic GVHD
treatment with no signs of active disease. The latter patient is only
6 months after BMT and still on IVIG. The patients’ clinical
outcome and their basic cell -mediated and humoral-immune
reconstitution after BMT in summarized in table 5.
Quantification of TRECs and KRECs
Pre-transplant TREC and KREC levels were undetectable in all
patients as expected in RAG-2 SCID (data not shown). TREC and
KREC copies were quantified in order to assess the neogenesis of
newly produced T and B lymphocytes after BMT (Figs. 1 and 2).
Early peripheral presence of newly produced T lymphocytes was
observed in 8 of 10 (#3–10) patients at 2–4 months after BMT
(Fig. 1a). Of them, 6 patients continued to exhibit increased
thymic production of T cells over time which may reflect increased
thymic function. In contrast, 4 patients showed either stable or
decreased levels of TRECs (Fig. 1b). These findings were in
agreement with the patients’ clinical outcome. At 2–4 months after
BMT, 2 patients who later displayed poor outcome (#1 and #2)
had undetectable or barely detectable TREC copies (0 and 4
copies, respectively). In contrast, the 8 patients who survived the
transplant (#3–10) had detectable TREC levels (ranging from 9 to
798 copies). In this latter group, no change was detected when
comparing the patients who were completely well after the
transplant (#6–10) with the patients who later developed
transplant-related complications, mainly cGVHD (#3–5). How-
ever, the former group of patients tended to have higher levels of
TREC compared to the latter group (201 vs. 48.5 average TREC
copies, respectively). Uninterrupted monitoring of the TREC
levels for up to 18 months after the transplant in these patients
revealed gradually increased levels in all patients who remained
well after the BMT (#6–10, Fig. 1b, lower panel) compared to 2
patients who developed cGVHD (#3–4, Fig. 1b, upper panel).
Patients #1 and #2 continued to show undetectable or barely
detectable TREC levels during 24 months of follow-up. Despite
having developed cGVHD, patient #5 showed elevated levels of
TREC overtime.
Early peripheral presence of newly produced B lymphocytes in
the various patients was detected after BMT. KRECs were
detected early in 4 of the 10 patients (#7–10) (Fig. 2a), and all of
them had received pre-transplant conditioning. Three patients
(#4–6) had a delayed presentation of KRECs, and three patients
(#1–3) had undetectable levels of KRECs (Fig. 2b). In order to
distinguish between newly produced B lymphocytes carrying signal
joint episomes and replicating cells carrying only the coding joint
rearrangements, measurements of these 2 distinct sequences were
carried out in the patients with the early presentation of KRECs
(#7–10). Most of the detected B cells in those patients had signal
joint episomes (an average of 88% compared to an average of 20%
that was observed in 4 aged-matched healthy controls, Fig. 2c),
suggesting B cell neogenesis rather than peripheral replication in
these patients. These findings were in agreement with the clinical
outcome of these patients. Specifically, patients #1 and #2, who
died within 24–36 months post-BMT, and patients #3, #4 and
#5, who developed cGVHD, had undetectable levels of KRECs
at 2–4 months after BMT, while 4 of the 5 patients who were well
after BMT (#7–10) had detectable levels of KRECs at that same
time point. Indeed, these patients achieved stable KREC copies
during follow-up (Fig. 2b, lower panel) in contrast to patients #1–
3 who continued to have undetectable KREC levels (Fig. 2b,
upper panel). Two of the 3 patients with delayed presentation of
KRECs (#4 and #5) developed cGVHD.
Analysis of the T- and B-cell receptor genes
Although it is typically not expressed on the cell surface of TCR
a/b cells, the c-chain gene remains rearranged and can be used as
a marker for a proper diverse rearrangement of the TCR genes.
Therefore, we performed PCR analysis of TCRv c gene
rearrangements in peripheral blood obtained from the patients
before and after BMT. Analysis of 4 V c rearranged TCR genes
before BMT revealed different abnormal patterns: monoclonal in
3 patients, oligoclonal in 1 patient, and undetectable in 6 patients.
These patterns correlated with the clinical phenotypes of the
disease: the 4 patients who displayed the Omenn phenotype
(patients #1 and #7–9) had mono- or oligoclonal patterns, while
the SCID patients with no Omenn features had an undetectable
repertoire. A representative repertoire is given for each pattern in
figure 3a. Analysis of the 4 V c rearranged TCR genes at 3
months after BMT showed an abnormal pattern in all patients: it
was skewed in 9 patients and undetectable in 1 patient (Fig. 3b).
Despite early presentation of TRECs in 8 patients (#3–10),
analysis of the V c rearranged TCR gene pattern at the same time
was highly abnormal in these patients. Thus, unlike TREC
evaluation, early prediction of patients’ clinical outcome based on
the V c rearranged TCR gene pattern was not possible. During
follow-up, 7 of the patients started to display gradual improvement
in the pattern of their rearranged TCRv c genes (data not shown).
The two patients who did not survive (#1 and #2), however, had
continued to demonstrate a significant abnormal TCRv c pattern
which was in correlation with their undetectable TREC levels.
This abnormality was observed 4 and 16 months before they
succumbed (Fig. 3c) and was attributed to their severe infection
and chronic illness.
Each patient underwent PCR analysis of 2 distinct IgH BCR
gene rearrangements in peripheral blood obtained from them
before and after BMT. As expected, the BCR repertoire upon
diagnosis of SCID was completely abnormal (data not shown).
Between 2–4 months after BMT, they displayed different patterns
of the BCR repertoire in agreement with their clinical outcome.
Figure 2. Early presence of KREC and transplant-related morbidity. KREC signal joint (sj) copies were detected in all studied patients (#1–
#10) at either 2–4 months (a) or various time lengths (b) post-bone marrow transplant (BMT). KREC copies were determined by real-time quantitative
(RQ) PCR and calculated by comapring the obtained cycle threshold (Ct) for each patient to the Ct of the same patient’s KREC levels before
undergoing BMT, using the LLCt relative quantification analysis. The percent ratios between KREC-cj copies and KREC-sj copies were measured in
patients with early presentation of KRECs (#7–#10) (c). Four age-matched healthy individuals were used as controls. Each sample was detected in
triplicate in all experiments.
doi:10.1371/journal.pone.0030494.g002
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were found in 7, 1 and 2 patients, respectively, with a good
outcome (#6–10) comparing to 0, 3 and 7 patients, respectively,
with a poor outcome (#1–5) (Fig. 4a). Interestingly, patient #7,
who had abnormal BCR gene rearrangement 3 months after
BMT had a detectable KREC level at the same time. In order to
test if KREC is indeed an early marker for B cell immune
reconstitution, we also checked to see whether there was any
correlation of the KREC level with the appearance of the BCR
repertoire. As can be seen in Fig. 4b, an increased level of KREC
preceded the appearance of a normal polyclonal BCR repertoire
in patients #7 and #8, and most of the B cells had signal joint
episomes indicative of B cell neogenesis in both of them.
Analysis of human TCR gene rearrangement
The TCR is created through a sequential order of recombina-
tion events between the different TCR genes
(TCRD.TCRG.TCRB.TCRA). This sequential order also
occurs within each individual gene and can therefore represent
different stages of T cell maturation. In order to test if thymus
recovery after BMT includes the simultaneous appearance of cells
representing these different maturation stages, we measured 4
different TCR gene rearrangements in the peripheral blood of 5 of
our RAG-2 SCID study patients over time (Fig. 5). Various
rearrangements (TCRD-Dd2-Dd3, TCRD-Dd2-Jd1, TCRD-
Vd1-Jd1, TCRA-REC) were detected 2–18 months after trans-
plant in all of them. The amount of all these detected
rearrangements increased with time in 3 patients (#5, #8 and
#10) (Fig. 5a–d). In one patient (#3), however, all rearrangement
events decreased over time and did so in parallel to his clinical
deterioration, suggesting severe diffuse thymic suppression.
Interestingly, only the latest rearrangement event (REC) decreased
over time in another patient (#4, Fig. 5d), which may suggest a
specific thymic impairment post-BMT rather than the general
thymus suppression that had probably occurred in patient #3.
Importantly, only patients with no late transplant-related compli-
cations reached normal levels of rearrangement, such as that seen
in the healthy control for each event. The patients’ long-term
clinical outcome could be anticipated by our findings.
Discussion
RAG-2-deficient patients have the typical T-B-SCID-variant.
The undetectable TREC and KREC levels pre-transplantation
common to all the patients in our cohort is clearly indicative of
absent or dysfunctional T and B cells. We demonstrated that high
proportions of T and B cells containing signal joints appeared
early after BMT, suggesting cell neogenesis rather than cell
proliferation. Their emergence was found to be closely related to
the patients’ clinical outcome as well as to their having undergone
pre-transplant conditioning.
T cells begin to engraft quickly after hematopoietic stem cell
transplantation, and substantial numbers of phenotypically mature
T cells can be detected in peripheral blood within 3 months after
transplantation. However, from 6 to 9 months are often required
before normal numbers of circulating CD3
+ T cells have been
reached, and further characterization of these cells almost always
reveals marked functional impairment and a markedly skewed
TCR repertoire [13,14]. Yet, even in the presence of considerable
peripheral T cell division causing skewed TCR repertoire, TREC
is present and can be detected. B cells reconstitute more slowly
than T cells, and 12 to 18 months are often required to achieve
relatively normal numbers of CD20
+ cells in peripheral blood [15].
Consequently, most RAG-2-deficient SCID patients need monthly
IVIG replacement therapy for a considerable period of time after
BMT, until full reconstitution of B cell immunity has been
achieved. Both T and B cell immune reconstitution ensure long-
term survival and reduce the risk of BMT-related complications,
mainly GVHD, infections and graft rejection [16]. Various studies
have been performed in order to test immune reconstitution after
BMT. In most of these studies, a successful immune reconstitution
after transplantation was significantly associated with favorable
clinical outcome [17–22]. Quantification of TRECs or analyses of
the TCR repertoire were the most advanced assays used to
determine immune reconstitution after BMT [23]. T-cell neogen-
esis became evident by 6 months, and normal levels of adult
thymic functions were restored at 6 to 12 months after BMT [24].
Morbidity and mortality after transplantation was found in
association with low TREC values [25] and BMT-related
complications, such as acute GVHD or its treatment, which had
a transient impact on TREC numbers [26]. In parallel, the TCR
repertoire is considerably abnormal during the first year after
transplantation, but it becomes normal with time, when full
immune reconstitution is achieved [27]. We demonstrated
peripheral presence of T cells containing signal joints early after
BMT procedures, indicating that they were donor-derived naive T
cells produced by the thymus, rather than proliferating cells.
Truly, low TREC content reflects either reduced thymus activity
or peripheral expansion [28]. However, in our case the latter is
irrelevant since we show an increase in TREC content post BMT,
which can be attributed only to the proliferation of new T cells
produced by the thymus. In addition, TREC quantification
carried out 3 months after BMT was found to be a useful tool that
indicated later mortality. In general, a better estimation of thymic
output eliminating factors that may affect TREC contents was
suggested, combining two mathematical models. These models are
based on calculating the rate of peripheral naive T cell production
(using Ki67 proliferation marker), and the dynamics of TRECs
[29]. A skewed TCR repertoire was still detected even when the
presence of TRECs was observed shortly after BMT. We speculate
that while ongoing immune responses recruited cells from the
naı ¨ve T-cell pool produced by the thymus, repopulation of the T-
cell compartment occurs through peripheral expansion of mature
T cells secondary to antigen exposure or triggered by self-peptides.
Similar to us, simultaneous quantification of TRECs and KRECs
which contain the required signal joint rearrangement in patients
with primary immunodeficiency after BMT was recently proposed
for monitoring the appearance of newly derived thymic and bone
marrow cells [30].
The different ordered TCR gene rearrangements that occur
during thymic maturation of T cells represent different stages of T
cell development [6]. We demonstrated that the various thymic
maturation stages occur simultaneously after BMT, despite the
presence of a skewed TCR repertoire. However, our patients
Figure 3. Abnormal rearrangement analysis of TCR-Vc pre- and post-bone marrow transplant (BMT). Four different Vc rearranged TCR
genes (Vc9.2, Vc11, VcF1, Vc10.2) were PCR amplified followed by Gene Scan analysis before (a) and after (b,c) BMT. A representative analysis for each
pattern before transplant is presented (a). The analysis of the Vc rearranged TCR genes in all studied patients 2–4 months post-BMT and an age-
matched healthy control is shown (b). The analysis of the Vc rearranged TCR genes in patients #1 and #2 at 4 and 16 months, respectively, before
they succumbed is shown, as well as an age-matched healthy control (c).
doi:10.1371/journal.pone.0030494.g003
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finding which may explain their clinical state during these events.
As such, the amount of all TCR rearranged genes was increased in
patients who had no BMT-related complications, while patients
who did have BMT-related complications failed to show either
general thymic suppression or late rearrangement events. The
latter finding suggests a specific and late thymic T cell maturation
defect. During that late stage of maturation, the AIRE protein is
known to be critical in controlling thymic negative selection and
ensuring that only self-tolerant T-cells are released [31]. This
mechanism prevents the development of autoimmune symptoms.
We and others have shown that patients who lack thymic
expression of AIRE exhibit similar T cell maturation defects
[32,33]. We now speculate that the breakdown of this central
tolerance mechanism may contribute to the development of late
autoimmune symptoms in these patients after BMT by allowing
auto-reactive clones to leak from the thymus.
B cell immune reconstitution and their early peripheral
presence after BMT has not been investigated in depth. Even
the decision when to discontinue gamma globulin treatment after
BMT is not certain, and many parameters, including the duration
of therapy, trough levels of serum IgM, IgG, or both, and/or the
ability to make antigen-specific antibody after immunization are
being considered. The majority of patients lacking donor B cells
will require immunoglobulin replacement for life [34]. The
presence of alloantibodies and high plasma B cell–activating
factor levels in patients with cGVHD suggests that altered B cell
homeostasis plays a role in disease pathogenesis, and that GVHD
and/or its treatment hamper B-lymphopoiesis [35,36]. It was
recently used to monitor the extent of B cell immune
reconstitution after BMT or enzyme replacement therapies for
adenosine deaminase-deficient SCID [37]. Although B cells are
known to be low in number or undetectable during the first 2
months after marrow grafting, we could detect the peripheral
presence of B cells containing signal joints early after BMT. Real-
time PCR detection of KRECs, despite undetectable FACS
detection of B cells, g clearly indicates that measurement of
KRECs is a more sensitive methodology. Furthermore, the early
detection of KRECs found in some patients, could be used to
anticipate their non long-term autoimmune BMT-related com-
plications. We also observed that only those patients who received
chemotherapy conditioning before BMT had early detectable
KRECs. In contrast to previous assumptions that chemotherapy
does not guarantee the development of that donor B cells, and
that the risks associated with chemotherapy outweigh the
potential for the development of B cell function, it is now widely
accepted that chemotherapy administered before transplantation
accelerates B cell immune reconstitution [38], as also shown by us
in the current study. The issue of whether the early appearance of
post-transplant B cells is due to their origin from the B cells
infused with the graft or from the infused stem cells is still under
debate. Since B cells containing signal joints do not duplicate
during subsequent cell divisions, they represent newly produced B
Figure 4. BCR rearrangement analysis and clinical outcome.
Two different IgH BCR gene rearrangements (FR2 and FR3) were PCR
amplified followed by Gene Scan analysis in all studied patients 2–4
months post-bone marrow transplant (BMT) and in an age-matched
healthy control (a). Parallel detection of KREC levels and the FR3 IgH
BCR gene rearrangement were PCR amplified, followed by RQ-PCR
analysis (KREC) or by Gene Scan analysis (BCR repertoire) in patients #7
(upper panel) and #8 (lower panel) from the time of BMT and up to one
year post-transplant. For KREC, both signal joint and coding joint were
examined (b).
doi:10.1371/journal.pone.0030494.g004
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cells released from the bone marrow [39]. As expected, when
there is a high rate of clonal and peripheral divisions in B cell
malignancies, the amount of KRECs decreases proportionally
[40]. Furthermore, even normal matured B cells which had
already been exposed to antigenic stimulations and had
undergone further divisions are known to carry smaller amounts
of KRECs. Thus, although both B cell-derived and stem cell-
derived B cells may theoretically coexist after grafting, we
demonstrated a higher proportion of B cells containing signal
joints early after BMT in patients who engrafted well and
successfully survived the BMT procedure. This is indicative of
early peripheral presence of B cells from their production and
maturation site and not B cells that had infused with the graft.
Thus, we can speculate that when engraftment is successful,
peripheral B cell homeostasis had originated mainly from B cells
containing signal joints rather than from matured B cell
proliferation. The results of our study suggest that measurement
of undetectable levels of KRECs early after BMT can be used to
plan the extension of personalized GVHD prophylactic treatment
in order to improve the clinical outcome of these patients. Since B
cell neogenesis precedes the peripheral appearance of IgG, and
assessment of host IgG production is not possible while patients
are on IVIG therapy, we suggest that early detectable levels of
KRECs can be used to consider shortening the duration of IVIG
therapy after BMT. Moreover, given that the maintenance of
immune surveillance requires the continuous supply of newly
produced lymphocytes, the evaluation of KRECs offers a better
marker for monitoring the efficacy of B cell compartment
regeneration, as recently suggested by Serana et al [37].
The heterogeneity of our study population in terms of age at the
time of transplant, the type of the donors and the conditioning
protocols are possible limitations of this work. A recent report
showed that the outcome after BMT for SCID is irrespective of
donor choice, the conditioning regimen used, and the underlying
genetic diagnosis. The overall improved survival is related to a
reduced rate of infections which can be due to early diagnosis [41],
or to early immune reconstitution, as we suggest. This needs to be
verified by further prospective studies using similar pre-transplant
parameters, given the small number of patients and the inter-
patient variability of our cohort.
To summarize, a unique group of patients with profoundly
depleted baseline T and B cell immunity was used to track the
kinetics of T and B cell immune recovery after BMT. We showed
that the early peripheral presence of newly produced B and T
lymphocytes from their production and maturation sites indicated
a donor stem cell origin. Early release of newly produced B and T
lymphocytes was closely associated with disease outcome.
Determination of immune reconstitution involves T and B cell
recovery and ability to maintain immune tolerance. These
capabilities will help to ensure successful engraftment, prevent
infection and other BMT-related complications, and provide
tolerance to self-antigens. TREC and KREC quantification are
important assays for monitoring T and B cell neogenesis and
homeostasis after BMT, and, as such, can serve as tools to monitor
outcome and to tailor individualized therapy.
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